PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-9.81%
Negative net income growth while CRWV stands at 7.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.13%
Less D&A growth vs. CRWV's 26.15%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.89%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
410.00%
Inventory growth of 410.00% while CRWV is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
No Data
No Data available this quarter, please select a different quarter.
-95.33%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
-21.20%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
21.33%
Some CapEx rise while CRWV is negative at -74.30%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
-303.92%
Negative yoy purchasing while CRWV stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
40.00%
Less 'other investing' outflow yoy vs. CRWV's 202.79%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-160.44%
Both yoy lines negative, with CRWV at -70.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-22.35%
Negative yoy issuance while CRWV is 4.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
31.43%
Buyback growth of 31.43% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.